Cabozantinib Promising for Metastatic Pheochromocytomas, Paragangliomas
Overall response rate was 25.0 percent in phase 2 study involving 17 patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Overall response rate was 25.0 percent in phase 2 study involving 17 patients
Only registered members have full access to PracticeUpdate content.